Ipratropium Bromide/Salbutamol Neutec

Ipratropium bromide and salbutamol, the active ingredients in Ipratropium Bromide/Salbutamol Neutec, are an anticholinergic and a short‑acting β2‑agonist respectively, presented as a combination inhalation product for inhalation use. They treat bronchospasm associated with chronic obstructive pulmonary disease (COPD) and asthma. GNH USA supplies Ipratropium Bromide/Salbutamol Neutec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium Bromide/Salbutamol Neutec is used to manage bronchospasm in chronic obstructive pulmonary disease and asthma, providing rapid bronchodilation. - COPD: relieves bronchospasm and improves airflow during exacerbations. - Asthma: provides quick relief of acute bronchoconstriction and improves breathing. - Acute bronchospasm: delivers rapid bronchodilation to ease airway constriction.

Ipratropium Bromide/Salbutamol Neutec may cause a range of adverse reactions.

Common Side Effects: - Cough or throat irritation - Dry mouth - Tremor or shakiness - Headache - Palpitations - Nausea

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe cardiac arrhythmia - Anaphylactic reaction or angioedema - Significant tachycardia - Hypokalemia - Acute pulmonary edema

Before prescribing Ipratropium Bromide/Salbutamol Neutec, consider the following precautions. - Assess lung function: evaluate baseline respiratory status prior to initiation. - Cardiovascular caution: use carefully in patients with known heart disease. - Hypersensitivity: avoid in individuals with documented allergy to either component. - Monitor for paradoxical bronchospasm: discontinue if severe worsening occurs. - Drug interactions: review concomitant medications for potential additive effects. - Store at room temperature: keep in original container, protect from moisture and heat.

Ipratropium Bromide/Salbutamol Neutec can interact with several drug classes.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator efficacy. - MAO inhibitors: risk of severe hypertension. - Tricyclic antidepressants: increased cardiac adverse effects. - Other anticholinergics: additive anticholinergic load. - Diuretics: may exacerbate hypokalemia.

Moderate Interactions (Monitor Closely): - Theophylline: heightened risk of tachycardia. - Inhaled corticosteroids: potential for oral thrush. - Diabetes medications: monitor blood glucose as β2‑agonists can affect levels.